“We are thrilled to welcome Dr Manos Perros as our new Chairman of the Board and Dr Marco Taglietti as an Independent Member” said Frank Kalkbrenner, former Chairman of the Board, representing Boehringer Ingelheim, main shareholder of AUROBAC THERAPEUTICS.
“As former CEOs of biotech companies which have successfully developed anti-infectives, their wealth of experience and strategic vision will be instrumental in guiding AUROBAC’s future endeavors. We believe that their appointment will further strengthen our Board and enhance our ability to pursue our mission to develop and bring to market innovative products to fight AMR.”
AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance
AUROBAC ©2024 – Legal Notice – Privacy Statement – Photo Credits